Shares of Iovance Biotherapeutics surged 13.4% to $16.79 in after-hours trading on October 28 after the company teased positive results from its lung cancer trial — only for the stock to crater as much as 35% the next day once investors digested the actual numbers. The whipsaw captures the central tension facing this fast-growing but unprofitable biotech: a promising cancer therapy chasing the biggest market in oncology, with data that may not be strong enough to get there.

  • A 25% Response Rate Sounds Good Until Wall Street Wanted More. As of the October 14 data cutoff, 17 of 69 patients responded to treatment, producing a 24.6% overall response rate — a measure of how many tumors shrank significantly. That was consistent with the 25.6% seen in an earlier, smaller group but fell short of market expectations, triggering investor concern. For a therapy that must compete in the $9 billion U.S. second-line lung cancer treatment market, valued at $8.95 billion in 2025 , the bar is high.

  • A Subgroup Tells a Better Story — If the FDA Buys It. A subgroup of 22 patients whose tumors lacked certain genetic mutations achieved a 59.1% response rate, accounting for 13 of 17 total responses.

Iovance estimates roughly 45% of newly diagnosed U.S. non-squamous metastatic lung cancer cases could meet these biomarker criteria , a potentially large addressable population. The company plans to begin enrollment in a biomarker-enriched registrational cohort in November 2026 , targeting a supplemental FDA filing in 2027. Regulatory success here is far from guaranteed — retrospective subgroup analyses often don't hold up prospectively.

  • The Commercial Engine Is Running, But Cash Is Still Burning. Iovance raised its full-year 2026 revenue guidance to $410–$420 million , driven by its already-approved melanoma therapy. Q2 revenue hit a record $99.3 million with 56% gross margin. Yet the company continues burning cash, with free cash flow at negative $66.3 million last quarter. A lung cancer approval would dramatically expand the revenue ceiling; without it, investors are paying a premium for a single-product company.

  • The Stock's Violent Reversal Tells Its Own Story. Shares fell 35.4% on October 29 after the webcast revealed details. Across 12 major market shocks, Iovance has dropped 50% or more five times. This stock rewards conviction — and punishes it in equal measure. Investors betting on the lung cancer expansion are now wagering on prospective data that won't arrive until 2027 at the earliest.